The window Jacksonville has been waiting on is almost open.
Jacksonville is one of those large, geographically dispersed Florida markets where the longevity-and-hormone-optimization activity is concentrated in a handful of specific neighborhoods rather than spread across the whole city. The cluster runs along the San Marco and Riverside corridors, out through Mandarin and Baymeadows, and east into the Beaches and Ponte Vedra. Mayo Clinic's Jacksonville campus anchors a serious academic medicine presence on the Southside, and the city's Naval Air Station population produces a steady inflow of younger active-duty and retired patients with practical interest in recovery and performance protocols. Both of those threads feed legitimate demand into the same pool of licensed providers.
The short version: in 2023 the FDA placed several named peptides — including BPC-157, KPV, TB-500, MOTs-C, and others — into Category 2 of the 503A bulk substances list, which restricts but does not prohibit compounding. On April 16, 2026 a Federal Register notice reopened the nominations process. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to review the science and vote on whether those compounds move into Category 1 (clearly compoundable under 503A) or stay in Category 2. Whatever the committee decides, the Jacksonville providwrs preparing for that meeting are about to be in a very different position than they were eighteen months ago.
Florida itself helped clear the runway. Senate Bill 1768, signed in 2023, explicitly preserved 503A compounding authority within the state and codified the prescriber-pharmacy relationship that this entire category depends on. That is one reason Jacksonville endocrinology and longevity practices have been able to keep working with licensed compounding pharmacies through a period when other states tightened up. Find Peptide Clinics exists to make that legitimate, licensed lane easy to find — and to make the gray-market storefronts easy to avoid.